Bausch Health Companies Inc. Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31)
Bausch Health Companies Inc. (BHC) had Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) of $91.03 million as of 2013-06-30, per its 10-Q filed 2013-08-07.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValueCurrent · last filed 2013-08-07
- 2013-06-30: Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) $91.03M.
- 2013-03-31: Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) $97.52M.
- 2012-12-31: Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) $102.56M.
- 2012-09-30: Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) $112.27M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value, Current (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $91.03M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $97.52M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $102.56M 10-Q · filed 2013-08-07 |
| 2012-09-30 | $112.27M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $67.11M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $92.35M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $100.26M 10-K · filed 2013-02-28 |
| 2011-09-30 | $145.61M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $111.01M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |